nach oben

Erschienen in:

01.08.2016 | Epidemiology

A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago

verfasst von: Talia Donenberg, Humayun Ahmed, Robert Royer, Shiyu Zhang, Steven A. Narod, Sophia George, Mohammad R. Akbari, Jameel Ali, Judith Hurley

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The mortality rate from breast cancer in the nation of Trinidad and Tobago is among the highest of any country in the Caribbean region. The contribution of inherited gene mutations to the burden of breast cancer in Trinidad and Tobago has not been studied. We examined the prevalence of mutations in three susceptibility genes (BRCA1, BRCA2, and PALB2) in breast cancer patients in Trinidad and Tobago. We studied 268 unselected breast cancer patients from Trinidad and Tobago and looked for mutations across the entire coding sequences of BRCA1, BRCA2, and PALB2. Overall, 28 of 268 patients (10.4 %) had a mutation in one of the three genes, including 15 in BRCA1, ten in BRCA2, two in PALB2, and one in both BRCA2 and PALB2. There were 25 different mutations identified; of these, four mutations were seen in two patients each. Given the high prevalence of mutations, it is reasonable to offer genetic testing for these three genes to all breast cancer patients in Trinidad and Tobago.

Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr

Warner WA, Morrison RL, Lee TY et al (2015) Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago. Cancer Med 4:1747–1753. doi:10.1002/cam4.503 CrossRef

Naraynsingh V, Hariharan S, Dan D et al (2009) Trends in breast cancer mortality in Trinidad and Tobago—a 35-year study. Cancer Epidemiol 34(1):20–23CrossRefPubMed

Hennis AJ, Hambleton IR, Wu SY et al (2009) Breast cancer incidence and mortality in a Caribbean population: comparisons with African–Americans. Int J Cancer 124(2):429–433CrossRefPubMedPubMedCentral

Luciani S, Cabanes A, Preito-Lara E et al (2013) Cervical and female breast cancers in the Americas: current situation and opportunities for action. Bull World Health Organ 91(9):640–649CrossRefPubMedPubMedCentral

Camacho-Rivera M, Ragin C, Roach V et al (2015) Breast cancer clinical characteristics and outcomes in Trinidad and Tobago. J Immigr Minor Health 17(3):765–772CrossRefPubMed

Taioli E, Attong-Rogers A, Layne P et al (2010) Breast cancer survival in women of African descent living in the US and in the Caribbean: effect of place of birth. Breast Cancer Res Treat 122(2):515–520CrossRefPubMed

Donenberg T, Lunn J, Curling D et al (2011) A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat 125(2):591–596CrossRefPubMed

Akbari MR, Donenberg T, Lunn J et al (2013) The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet 85:64–67. doi:10.1111/cge.12132 CrossRefPubMed

10.

Easton D (1994) The inherited component of cancer. Br Med Bull 50:527–535PubMed

11.

Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665–676CrossRefPubMed

12.

Claus EB, Schildkraut JM, Thompson WD et al (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324CrossRefPubMed

13.

Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedPubMedCentral

14.

Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 106(17):7155–7160. doi:10.1073/pnas.0811159106 CrossRefPubMedPubMedCentral

15.

Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. NEJM 371(6):497–506. doi:10.1056/NEJMoa1400382 CrossRefPubMedPubMedCentral

16.

Warner E, Foulkes W, Goodwin P et al (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91(14):1241–1247CrossRefPubMed

17.

Metcalfe KA, Poll A, Royer R et al (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28(3):387–391CrossRefPubMed

18.

Tanabe R. Trinidad and Tobago [Internet], New World Encyclopedia. Available from: http://www.newworldencyclopedia.org/p/index.php?title=Trinidad_and_Tobago&oldid=992842

19.

Donenberg T, George S, Akbari M et al (2014) Evaluation of Bahamian BRCA founder mutations in the Caribbean. Curr Oncol 21(2):e358–e391CrossRef

20.

Szabo C, Masiello A, Ryan JF et al (2000) The breast cancer information core: database design, structure, and scope. Hum Mutat 16:123–131CrossRefPubMed

21.

Olopade OI, Fackenthal JD, Dunston G et al (2003) Breast cancer genetics in African Americans. Cancer 97:236–245. doi:10.1002/cncr.11019 CrossRefPubMed

22.

Fackenthal KD, Zhang J, Zhang B et al (2012) High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer 131:1114–1123. doi:10.1002/ijc.27326 CrossRefPubMed

23.

Churpek JE, Walsh T, Zheng Y et al (2015) Inherited predisposition to breast cancer among African American women. Breast Cancer Res Tr 149:31–39. doi:10.1007/s10549-014-3195-0 CrossRef

24.

Gao Q, Neuhausen S, Cummings S et al (1997) Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast. Am J Hum Genet 60:1233–1236PubMedPubMedCentral

25.

Laitman Y, Borsthein RT, Stoppa-Lyonnet D et al (2011) Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Tr 127:489–495. doi:10.1007/s10549-010-1217-0 CrossRef

26.

Vezina H, Durocher F, Dumont M et al (2005) Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet 117:119–132. doi:10.1007/s00439-005-1297-9 CrossRefPubMed

27.

Blesa JR, García JA, Ochoa E (2000) Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. Hum Mutat 15:381–382CrossRefPubMed

28.

Dutil J, Golubeva VA, Pacheco-Torres AL et al (2015) The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Tr 154(3):441–453. doi:10.1007/s10549-015-3629-3 CrossRef

29.

Caux-Moncoutier V, Castera L (2010) EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1525 patients. Hum Mutat 32(3):325–334. doi:10.1002/humu.21414 CrossRef

30.

Desmond A, Kurian A, Gabree M et al (2015) Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol 1(7):943–951. doi:10.1001/jamaoncol.2015.2690 CrossRefPubMed

31.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA (2015) Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 1(3):306–313CrossRefPubMed

32.

Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 11(348):g226CrossRef

33.

Finch AP, Lubinski J, Møller P et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32(15):1547–1553CrossRefPubMedPubMedCentral

Titel: A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago
verfasst von: Talia Donenberg
Humayun Ahmed
Robert Royer
Shiyu Zhang
Steven A. Narod
Sophia George
Mohammad R. Akbari
Jameel Ali
Judith Hurley
Publikationsdatum: 01.08.2016
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3870-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Phase II studies of two different schedules of dasatinib in ***bone metastasis predominant metastatic breast cancer: SWOG S0622

Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study

Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer

Lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer

Author’s response to “letter to the editor: lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer”

Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie